Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 7, Issue 2 (2018)

Aqueous ethanolic extract of Acalypha inferno accelerates the clearance of glucose in normoglycaemic rats

Author(s):
Christopher Larbie, Juliana Oduro and Jesse John Tofah
Abstract:
Glucose tolerance refers to the body’s ability to metabolise glucose within a stipulated time interval. Failure of the body to use glucose results in hyperglycaemia and progressively to diabetes. Acalypha inferno (family Euphorbiaceae) is an ornamental plant found widely in the tropics of Africa and known for its phytoremediating properties. The study was aimed at investigating the effects of aqueous ethanolic extract of Acalypha inferno on oral glucose tolerance in normoglycaemic rats. A 50% hydro-ethanolic extract of the leaves was prepared, and the oral glucose tolerance effect of the plant assessed for 14 days in normoglycaemic rats at doses of 100mg, 250mg and 500mg/kg body weight. Glibenclamide (10mg/kg) was used as a standard drug. The effect of treatment on body weight, OGTT at day 7 and 14, lipid profile and kidney function were assessed. On day 7, FBG level increased from 4.93±0.29mmol/l to 25.03±0.93mmol/l after 1 hour and 17.53±4.50mmol/l after 3 hours in normal group. Extract and drug treated groups prevented such increases at all doses (p<0.001). FBG levels were restored to basal levels after 8 hours. Total cholesterol increased in the 250 mg group with a significant increase in LDL levels in the 100mg, 250mg and 500mg group compared to the normal. There was no significant difference in relative kidney weight, urea and creatinine levels. The hydro-ethanolic extract of Acalypha inferno possesses glucose tolerance abilities in normoglycaemic rats.
Pages: 79-83  |  1234 Views  132 Downloads


The Pharma Innovation Journal
How to cite this article:
Christopher Larbie, Juliana Oduro, Jesse John Tofah. Aqueous ethanolic extract of Acalypha inferno accelerates the clearance of glucose in normoglycaemic rats. Pharma Innovation 2018;7(2):79-83.

Call for book chapter